Oncolytics Biotech (TSE:ONC) Stock Price Up 14.5% – Here’s Why

Oncolytics Biotech Inc. (TSE:ONC)’s stock price shot up 14.5% on Thursday . The stock traded as high as C$1.26 and last traded at C$1.26. 243,945 shares traded hands during trading, an increase of 230% from the average session volume of 73,919 shares. The stock had previously closed at C$1.10.

Analyst Ratings Changes

Separately, Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Stock Performance

The firm’s fifty day moving average is C$1.45 and its 200 day moving average is C$1.40. The firm has a market capitalization of C$91.46 million, a price-to-earnings ratio of -3.13 and a beta of 1.35. The company has a debt-to-equity ratio of 6.09, a current ratio of 4.99 and a quick ratio of 8.86.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.